Martínez BD

Idioma: Español
Referencias bibliográficas: 50
Paginas:
Archivo PDF: 61.94 Kb.

RESUMEN

La liberación controlada de fármacos en el sitio del tumor y el desarrollo de técnicas no invasivas de monitoreo constituyen 2 de los principales retos que enfrentan las terapias antitumorales en la actualidad. En este trabajo se analizan algunas de las potencialidades del uso de liposomas como vehículos para el transporte de drogas hasta los tumores, especialmente de las variantes direccionalizadas a antígenos tumorales mediante el acoplamiento de anticuerpos (inmunoliposomas). Estas vesículas pueden a su vez ser utilizadas en combinación con el uso de imágenes de resonancia magnética, una de las técnicas de imagenología más utilizadas y de mayores potencialidades en la visualización a nivel molecular. El uso conjunto de estas 2 tecnologías permite controlar la cantidad de fármaco administrado, así como predecir la eficacia del tratamiento y monitorear la progresión de este

REFERENCIAS (EN ESTE ARTÍCULO)

1. Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst. 2006;98(5):335-44.

2. Sorg BS, Moeller BJ, Donovan O, Cao Y, Dewhirst MW. Hyperspectral imaging of hemoglobin saturation in tumor microvasculature and tumor hypoxia development. J Biomed Opt. 2005;10(4):44004.

3. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11(1):83-95.

4. Webb A. Introduction to biomedical imaging. NJ: Hoboken; 2003.

5. Allport JR, Weissleder R. In vivo imaging of gene and cell therapies. Exp Hematol. 2001;29(11):1237-46.

6. Lanza GM, Lamerichs R, Caruthers S, Wickline SA. Molecular imaging in MR with targeted paramagnetic nanoparticles. Medicamundi. 2003;47(1):10-6.

7. Phelps ME. PET: the merging of biology and imaging into molecular imaging. J Nucl Med. 2000;41(4):661-81.

8. Weissleder R, Simonova M, Bogdanova A, Bredow S, Enochs WS, Bogdanov A, Jr. MR imaging and scintigraphy of gene expression through melanin induction. Radiology. 1997;204(2):425-9.

9. Liang HD, Blomley MJK. The role of ultrasound in molecular imaging. Br J Radiol. 2003;76(S2):140-50.

10. Baeten J, Haller J, Shih H, Ntziachristos V. In vivo investigation of breast cancer progression by use of an internal control. Neoplasia. 2009;11(3):220-7.

11. Sipkins DA, Gijbels K, Tropper FD, Bednarski M, Li KC, Steinman L. ICAM-1 expression in autoimmune encephalitis visualized using magnetic resonance imaging. J Neuroimmunol. 2000;104(1):1-9.

12. Lanza GM, Winter PM, Caruthers SD, Morawski AM, Schmieder AH, Crowder KC, et al. Magnetic resonance molecular imaging with nanoparticles. J Nucl Cardiol. 2004;11(6):733-43.

13. Gupta H, Weissleder R. Targeted contrast agents in MR imaging. Magn Reson Imaging Clin N Am. 1996;4(1):171-84.

14. Strijkers GJ, Hak S, Kok MB, Springer CS, Jr., Nicolay K. Three-compartment T1 relaxation model for intracellular paramagnetic contrast agents. Magn Reson Med. 2009;61(5):1049-58.

15. Glogard C, Stensrud G, Hovland R, Fossheim SL, Klaveness J. Liposomes as carriers of amphiphilic gadolinium chelates: the effect of membrane composition on incorporation efficacy and in vitro relaxivity. Int J Pharm. 2002;233(1-2):131-40.

16. De Schepper AM, Bloem JL. Soft tissue tumors: grading, staging, and tissue-specific diagnosis. Top Magn Reson Imaging. 2007;18(6):431-44.

17. He Q, Xu RZ, Shkarin P, Pizzorno G, Lee-French CH, Rothman DL, et al. Magnetic resonance spectroscopic imaging of tumor metabolic markers for cancer diagnosis, metabolic phenotyping, and characterization of tumor microenvironment. Dis Markers. 2003;19(2-3):69-94.

18. Kwee TC, Takahara T, Ochiai R, Nievelstein RA, Luijten PR. Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology. Eur Radiol. 2008;18(9):1937-52.

19. Kiessling F, Morgenstern B, Zhang C. Contrast agents and applications to assess tumor angiogenesis in vivo by magnetic resonance imaging. Curr Med Chem. 2007;14(1):77-91.

20. Kiessling F, Huppert J, Zhang C, Jayapaul J, Zwick S, Woenne EC, et al. RGD-labeled USPIO inhibits adhesion and endocytotic activity of alpha v beta3-integrin-expressing glioma cells and only accumulates in the vascular tumor compartment. Radiology. 2009;253(2):462-9.

21. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145-60.

22. Huang SK, Stauffer PR, Hong K, Guo JW, Phillips TL, Huang A, et al. Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. Cancer Res. 1994;54(8):2186-91.

23. Torchilin VP. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 2007;9(2):E128-47.

24. Kong G, Braun RD, Dewhirst MW. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res. 2000;60(16):4440-5.

25. Kong G, Braun RD, Dewhirst MW. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res. 2001;61(7):3027-32.

26. Lokling KE, Skurtveit R, Bjornerud A, Fossheim SL. Novel pH-sensitive paramagnetic liposomes with improved MR properties. Magn Reson Med. 2004;51(4):688-96.

27. Needham D, Anyarambhatla G, Kong G, Dewhirst MW. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res. 2000;60(5):1197-201.

28. Viglianti BL, Abraham SA, Michelich CR, Yarmolenko PS, MacFall JR, Bally MB, et al. In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: illustration of targeted delivery. Magn Reson Med. 2004;51(6):1153-62.

29. Fossheim SL, Il'yasov KA, Hennig J, Bjornerud A. Thermosensitive paramagnetic liposomes for temperature control during MR imaging-guided hyperthermia: in vitro feasibility studies. Acad Radiol. 2000;7(12):1107-15.

30. Barenholz Y. Relevancy of drug loading to liposomal formulation therapeutic efficacy. J Liposome Res. 2003;13(1):1-8.

31. Senior J, Gregoriadis G. Is half-life of circulating liposomes determined by changes in their permeability? FEBS Lett. 1982;145(1):109-14.

32. Harashima H, Sakata K, Funato K, Kiwada H. Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes. Pharm Res. 1994;11(3):402-6.

33. Drummond DC, Noble CO, Hayes ME, Park JW, Kirpotin DB. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J Pharm Sci. 2008;97(11):4696-740.

34. Siwak DR, Tari AM, Lopez-Berestein G. The potential of drug-carrying immunoliposomes as anticancer agents. Commentary re: J. W. Park et al., Anti-HER2 immunoliposomes: enhanced efficacy due to targeted delivery. Clin Cancer Res. 2002;8:1172-81. Clin Cancer Res. 2002;8(4):955-6.

35. Harding JA, Engbers CM, Newman MS, Goldstein NI, Zalipsky S. Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes. Biochim Biophys Acta. 1997;1327(2):181-92.

36. Winter G, Harris WJ. Humanized antibodies. Immunol Today. 1993;14(6):243-6.

37. Pan H, Han L, Chen W, Yao M, Lu W. Targeting to tumor necrotic regions with biotinylated antibody and streptavidin modified liposomes. J Control Release. 2008;125(3):228-35.

38. Navon G, Panigel R, Valensin G. Liposomes containing paramagnetic macromolecules as MRI contrast agents. Magn Reson Med. 1986;3(6):876-80.

39. Unger EC, Winokur T, MacDougall P, Rosenblum J, Clair M, Gatenby R, et al. Hepatic metastases: liposomal Gd-DTPA-enhanced MR imaging. Radiology. 1989;171(1):81-5.

40. Kamaly N, Kalber T, Ahmad A, Oliver MH, So PW, Herlihy AH, et al. Bimodal paramagnetic and fluorescent liposomes for cellular and tumor magnetic resonance imaging. Bioconjug Chem. 2008;19(1):118-29.

41. Mulder WJ, Douma K, Koning GA, van Zandvoort MA, Lutgens E, Daemen MJ, et al. Liposome-enhanced MRI of neointimal lesions in the ApoE-KO mouse. Magn Reson Med. 2006;55(5):1170-4.

42. Erdogan S, Roby A, Sawant R, Hurley J, Torchilin VP. Gadolinium-loaded polychelating polymer-containing cancer cell-specific immunoliposomes. J Liposome Res. 2006;16(1):45-55.

43. Erdogan S, Medarova ZO, Roby A, Moore A, Torchilin VP. Enhanced tumor MR imaging with gadolinium-loaded polychelating polymer-containing tumor-targeted liposomes. J Magn Reson Imaging. 2008;27(3):574-80.

44. Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res. 2002;8(4):1172-81.

45. Matsumura Y, Gotoh M, Muro K, Yamada Y, Shirao K, Shimada Y, et al. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol. 2004;15(3):517-25.

46. Matteucci ML, Anyarambhatla G, Rosner G, Azuma C, Fisher PE, Dewhirst MW, et al. Hyperthermia increases accumulation of technetium-99m-labeled liposomes in feline sarcomas. Clin Cancer Res. 2000;6(9):3748-55.

47. Frich L, Bjornerud A, Fossheim S, Tillung T, Gladhaug I. Experimental application of thermosensitive paramagnetic liposomes for monitoring magnetic resonance imaging guided thermal ablation. Magn Reson Med. 2004;52(6):1302-9.

48. Viglianti BL, Ponce AM, Michelich CR, Yu D, Abraham SA, Sanders L, et al. Chemodosimetry of in vivo tumor liposomal drug concentration using MRI. Magn Reson Med. 2006;56(5):1011-8.

49. Ponce AM, Viglianti BL, Yu D, Yarmolenko PS, Michelich CR, Woo J, et al. Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. J Natl Cancer Inst. 2007;99(1):53-63.

50. Ahmed M, Goldberg SN. Combination radiofrequency thermal ablation and adjuvant IV liposomal doxorubicin increases tissue coagulation and intratumoural drug accumulation. Int J Hyperthermia. 2004;20(7):781-802.